Ventricular tachycardia pathophysiology: Difference between revisions

Jump to navigation Jump to search
 
(32 intermediate revisions by 7 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Ventricular tachycardia}}
{{Ventricular tachycardia}}
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}


==Overview==  
==Overview==  
The underlying mechanism of VT is due to [[automaticity]] arising in either the [[myocardium]] or in the distal conduction system. The most common underlying substrate for ventricular tachycardia is [[ischemic heart disease]]. The morphology of ventricular tachycardia often depends on its cause.
The underlying mechanism of [[VT]] is due to [[automaticity]] arising in either the [[myocardium]] or in the distal [[conduction system]]. The most common underlying substrate for [[ventricular tachycardia]] is [[ischemic heart disease]]. [[ Myocardial]] scarring from any process increases the likelihood of electrical [[reentrant]] circuits. These circuits generally include a zone where normal electrical propagation is slowed by the scar. [[Ventricular]] scar formation from a prior [[Myocardial infarction|myocardial infarction (MI)]] is the most common cause of sustained [[monomorphic VT]]. The morphology of [[ventricular tachycardia]] often depends on its cause. [[VT]] in a [[structurally normal heart]] typically results from mechanisms such as triggered activity and enhanced [[automaticity]]. If [[VT]] is hemodynamically tolerated, the incessant [[tachyarrhythmia]] may cause a [[dilated cardiomyopathy]]. This may develop over a period of weeks to years and may resolve with successful suppression of the [[VT]].


==Pathophysiology==
==Pathophysiology==
Pathophysiology of ventricular tachycardia can be better studied depending upon the subclass:<ref name="pmid28855272">{{cite journal |vauthors=Martin CA, Lambiase PD |title=Pathophysiology, diagnosis and treatment of tachycardiomyopathy |journal=Heart |volume=103 |issue=19 |pages=1543–1552 |date=October 2017 |pmid=28855272 |pmc=5629945 |doi=10.1136/heartjnl-2016-310391 |url=}}</ref><ref name="pmid9058854">{{cite journal |vauthors=Simons GR, Klein GJ, Natale A |title=Ventricular tachycardia: pathophysiology and radiofrequency catheter ablation |journal=Pacing Clin Electrophysiol |volume=20 |issue=2 Pt 2 |pages=534–51 |date=February 1997 |pmid=9058854 |doi=10.1111/j.1540-8159.1997.tb06209.x |url=}}</ref><ref name="pmid15137521">{{cite journal |vauthors=Brunckhorst C, Delacretaz E |title=[Ventricular tachycardia--etiology, mechanisms and therapy] |language=German |journal=Ther Umsch |volume=61 |issue=4 |pages=257–64 |date=April 2004 |pmid=15137521 |doi=10.1024/0040-5930.61.4.257 |url=}}</ref><ref name="pmid19589116">{{cite journal |vauthors=Srivathsan K, Ng DW, Mookadam F |title=Ventricular tachycardia and ventricular fibrillation |journal=Expert Rev Cardiovasc Ther |volume=7 |issue=7 |pages=801–9 |date=July 2009 |pmid=19589116 |doi=10.1586/erc.09.69 |url=}}</ref>
==== Cellular level ====
* [[Electrical reentry]] or abnormal [[automaticity]] is the main reason behind [[ventricular tachycardia]].
** [[Myocardial]] scarring from any process increases the likelihood of [[electrical reentrant circuits]].
** These circuits generally include a zone where normal electrical propagation is slowed by the [[scar]].
**[[ Ventricular scar]] formation from a prior [[Myocardial infarction|myocardial infarction (MI)]] is the most common cause of sustained monomorphic VT.
* [[VT]] in a structurally normal heart typically results from mechanisms such as triggered activity and enhanced [[automaticity]].
*[[Torsade de pointes]] seen in the [[Long QT syndrome|long QT syndromes]] is likely a combination of triggered activity and [[ventricular reentry]].
* During [[VT]], [[cardiac output]] is reduced as a consequence of decreased [[ventricular] filling from the rapid heart rate and the lack of properly timed or coordinated [[atrial]] contraction.
* [[Ischemia]] and [[mitral insufficiency]]  may also contribute to decreased [[ventricular]] stroke output and hemodynamic intolerance.
* Hemodynamic collapse is more likely when underlying [[left ventricular]] dysfunction is present or when [[heart rates ]] are very rapid.
* Diminished [[cardiac output]] may result in diminished [[myocardial perfusion]], worsening [[inotropic]] response, and degeneration to [[Ventricular fibrillation|ventricular fibrillation (VF)]], resulting in [[sudden death]].
* In [[patients]] with [[monomorphic VT]], [[mortality]] risk correlates with the degree of [[structural heart disease]]. Underlying [[structural heart diseases]] such as [[ischemic cardiomyopathy]], [[dilated cardiomyopathy]], [[hypertrophic cardiomyopathy]], [[Chagas disease]], and [[Right ventricular failure|right ventricular dysplasia]] have all been associated with degeneration of [[monomorphic ]] or [[polymorphic VT]] to [[VF]].
* Even without such degeneration, [[VT]] can also produce [[congestive heart failure]] and hemodynamic compromise, with subsequent [[morbidity ]] and [[mortality]].
* If [[VT]] is hemodynamically tolerated, the incessant [[tachyarrhythmia]] may cause a [[dilated cardiomyopathy]]. This may develop over a period of weeks to years and may resolve with successful suppression of the [[VT]].
===Monomorphic Ventricular Tachycardia===
===Monomorphic Ventricular Tachycardia===
There are two reasons the morphology of the QRS does not vary in [[monomorphic ventricular tachycardia]]:
*A single site that generates [[cardiac arrhythmia#origin of impulse|automaticity]] of a single point in either the left or right [[ventricle]].
*A [[cardiac arrhythmia#origin of impulse|reentry]] circuit within the [[ventricle]].
====Causes====
=====Common=====
*Scar from a prior [[MI]] (the most common cause of [[monomorphic ventricular tachycardia]])


=====Rare=====
* There are two reasons the morphology of the [[QRS]] does not vary in [[monomorphic ventricular tachycardia]]:
*[[Right ventricular dysplasia]]
**A single site that generates [[cardiac arrhythmia#origin of impulse|automaticity]] of a single point in either the left or right [[ventricle]].
*[[Right ventricular outflow tract VT]]
**A [[cardiac arrhythmia#origin of impulse|reentry]] circuit within the [[ventricle]].
*[[Left ventricular outflow tract VT]]
 
===[[Polymorphic Ventricular Tachycardia]]===
 
* [[Polymorphic ventricular tachycardia]], on the other hand, is most commonly caused by abnormalities of [[myocardium|ventricular muscle]] repolarization.
* The predisposition to this problem usually manifests on the [[ECG]] as a prolongation of the [[QT interval]].
* [[QT prolongation]] may be congenital or acquired.
* Congenital problems include [[long QT syndrome]] and [[catecholaminergic polymorphic ventricular tachycardia]].
* Acquired problems are usually related to [[drug toxicity]] or [[electrolyte abnormalities]], but can occur as a result of [[myocardial ischemia]].
* Class III [[anti-arrhythmic]] drugs such as [[sotalol]] and [[amiodarone]] prolong the [[QT interval]] and may in some circumstances be pro-arrhythmic.
* Other relatively common drugs including some [[antibiotics]] and [[antihistamines]] may also be a danger, particularly in combination with one another.
* Problems with [[blood]] levels of [[potassium]], [[magnesium]] and [[calcium]] may also contribute. High dose [[magnesium]] is often used as an [[antidote]] in [[cardiac arrest]] protocols.


===Polymorphic Ventricular Tachycardia===
===[[Bundle Branch Re-entrant Ventricular Tachycardia]]===
Polymorphic ventricular tachycardia, on the other hand, is most commonly caused by abnormalities of [[myocardium|ventricular muscle]] repolarization. The predisposition to this problem usually manifests on the EKG as a prolongation of the [[QT interval]]. [[QT prolongation]] may be congenital or acquired. Congenital problems include [[long QT syndrome]] and [[catecholaminergic polymorphic ventricular tachycardia]]. Acquired problems are usually related to drug toxicity or [[electrolyte abnormalities]], but can occur as a result of [[myocardial ischemia]]. Class III [[anti-arrhythmic]] drugs such as [[sotalol]] and [[amiodarone]] prolong the [[QT interval]] and may in some circumstances be pro-arrhythmic. Other relatively common drugs including some [[antibiotics]] and [[antihistamines]] may also be a danger, particularly in combination with one another. Problems with blood levels of [[potassium]], [[magnesium]] and [[calcium]] may also contribute. High dose [[magnesium]] is often used as an antidote in [[cardiac arrest]] protocols.


[[Image:VTMono.jpg|600 px|center|thumb|Monomorphic ventricular tachycardia]]
* [[Bundle branch reentry]] [[ventricular tachycardia]] usually occurs either in patients with [[structural heart disease]] or in patients with conduction disturbances with a structurally normal heart.  
* [[Bundle branch reentry]] is a macro-reentrant [[tachycardia]] that incorporates the [[His-Purkinje system]], the bundle branches, and trans-septal [[myocardial]] conduction in the circuit.
* Typical [[bundle branch reentry]] [[tachycardia]] uses the [[Purkinje fibers|right bundle]] as the anterograde limb and the [[Purkinje fibers|left bundle]] as the retrograde limb.
* Atypical [[bundle branch reentry]] uses the [[left bundle]] (anterior fascicle, posterior fascicle, or both) as the antegrade limb and the [[right bundle]] as the retrograde limb.
* The [[tachycardia]] appears as a typical [[left bundle branch block]] or [[right bundle branch block]].
===[[Accelerated idioventricular rhythm]]===
* [[Accelerated idioventricular rhythm]] commonly seen in the setting of [[reperfusion]] following [[myocardial]] [[ischemia]] or [[infarction]]. However, [[spontaneous coronary artery dissection]] should be considered when the [[atherosclotic disease]] is unlikely. <ref>{{cite journal|doi=10.1001/jamaintern-med.2020.8999}}</ref>


===Bundle Branch Re-entrant Ventricular Tachycardia===
*The [[Known]] [[mechanism]] is [[automaticity]] and can be seen in [[patients]] with  [[digoxin]] [[toxicity]] and rarely seen in [[structurally normal heart]]
Bundle branch reentry ventricular tachycardia usually occurs either in patients with structural heart disease or in patients with conduction disturbances with a structurally normal heart. Bundle branch reentry is a macro-reentrant [[tachycardia]] that incorporates the [[His-Purkinje system]], the bundle branches, and transseptal myocardial conduction in the circuit. Typical bundle branch reentry tachycardia uses the [[Purkinje fibers|right bundle]] as the anterograde limb and the [[Purkinje fibers|left bundle]] as the retrograde limb. Atypical bundle branch reentry uses the left bunde (anterior fascicle, posterior fascicle or both) as the antegrade limb and the right bundle as the retrograde limb. The tachycardia appears as a typical [[left bundle branch block]] or [[right bundle branch block]].
* Self-limited [[condition]], resolved spontaneously


==References==
==References==
{{reflist|2}}
{{reflist|2}}


[[Category:Best pages]]
[[Category:Up-To-Date cardiology]]
[[Category:Up-To-Date]]


[[Category:Disease]]
[[Category:Disease]]

Latest revision as of 05:41, 28 July 2021

Ventricular tachycardia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ventricular Tachycardia from other Disorders

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography

Cardiac MRI

Other Diagnostic Tests

Treatment

Medical Therapy

Electrical Cardioversion

Ablation

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ventricular tachycardia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ventricular tachycardia pathophysiology

CDC onVentricular tachycardia pathophysiology

Ventricular tachycardia pathophysiology in the news

Blogs on Ventricular tachycardia pathophysiology

to Hospitals Treating Ventricular tachycardia pathophysiology

Risk calculators and risk factors for Ventricular tachycardia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

The underlying mechanism of VT is due to automaticity arising in either the myocardium or in the distal conduction system. The most common underlying substrate for ventricular tachycardia is ischemic heart disease. Myocardial scarring from any process increases the likelihood of electrical reentrant circuits. These circuits generally include a zone where normal electrical propagation is slowed by the scar. Ventricular scar formation from a prior myocardial infarction (MI) is the most common cause of sustained monomorphic VT. The morphology of ventricular tachycardia often depends on its cause. VT in a structurally normal heart typically results from mechanisms such as triggered activity and enhanced automaticity. If VT is hemodynamically tolerated, the incessant tachyarrhythmia may cause a dilated cardiomyopathy. This may develop over a period of weeks to years and may resolve with successful suppression of the VT.

Pathophysiology

Pathophysiology of ventricular tachycardia can be better studied depending upon the subclass:[1][2][3][4]

Cellular level

Monomorphic Ventricular Tachycardia

Polymorphic Ventricular Tachycardia

Bundle Branch Re-entrant Ventricular Tachycardia

Accelerated idioventricular rhythm

References

  1. Martin CA, Lambiase PD (October 2017). "Pathophysiology, diagnosis and treatment of tachycardiomyopathy". Heart. 103 (19): 1543–1552. doi:10.1136/heartjnl-2016-310391. PMC 5629945. PMID 28855272.
  2. Simons GR, Klein GJ, Natale A (February 1997). "Ventricular tachycardia: pathophysiology and radiofrequency catheter ablation". Pacing Clin Electrophysiol. 20 (2 Pt 2): 534–51. doi:10.1111/j.1540-8159.1997.tb06209.x. PMID 9058854.
  3. Brunckhorst C, Delacretaz E (April 2004). "[Ventricular tachycardia--etiology, mechanisms and therapy]". Ther Umsch (in German). 61 (4): 257–64. doi:10.1024/0040-5930.61.4.257. PMID 15137521.
  4. Srivathsan K, Ng DW, Mookadam F (July 2009). "Ventricular tachycardia and ventricular fibrillation". Expert Rev Cardiovasc Ther. 7 (7): 801–9. doi:10.1586/erc.09.69. PMID 19589116.
  5. . doi:10.1001/jamaintern-med.2020.8999. Missing or empty |title= (help)

Template:WH Template:WS